AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates
July 31 (Reuters) – AbbVie trimmed its 2026 profit forecast on Friday to account for its planned Apogee Therapeutics āacquisition, while topping second-quarter estimates on strong immunology drug āsales. Shares of the drugmaker fell more than 4% in premarket trading. In June, āAbbVie agreed to buy Apogee for $10.9 billion, the company’s largest buyout in…
